Friday, 17 Nov 2017

You are here

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

This was a comparative cohort study of patients with psoriasis (N=197,130), PsA (N=12,308), RA (N=54,251), and matched controls (N=1,279,754). Researchers calculated the adjusted hazard ratios for any liver disease in these patients with or without systemic therapy (ST).  Liver disease was defined as any liver disease, non-alcoholic fatty liver disease (NAFLD), and cirrhosis (any etiology).

 Overall, 6% of psoriasis patients were prescribed systemic therapy, as were 53% of people with psoriatic arthritis and 61% of people with rheumatoid arthritis. MTX was the most commonly prescribed ST. 

The Liver Disease Hazard ratios were: 

Diseasewith MTX RxHazard Ratio
PsONo1.37
PsOYes1.97
PsANo1.38
PsAYes1.49
RANo 1.49
RA Yes0.96

 

Incident NAFLD was highest in patients with PsO prescribed a ST (2.23) and PsA with ST (2.11). Risk of cirrhosis was highest among patients with PsO with an ST (2.62) and PsA without a ST (3.15).

Increasing body surface area in PsO further increased the prevalence of liver disease and cirrhosis (p for trend <0.001).

More so than RA, PsO and PsA are associated with liver disease, particularly NAFLD and cirrhosis, and this was true even among patients without systemic therapy exposure.

Compared to people without chronic inflammatory diseases, people with psoriasis were 37% more likely to develop liver disorders. When psoriasis patients took methotrexate, they had roughly twice  (67%) the odds of liver damage.  For rheumatoid arthritis, there was no increased risk of liver disease when people took methotrexate, but when they didn’t they had 49% higher odds of liver damage.

There was no data on deaths from liver disease in this study

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Novartis Features Secukinumab Data at ACR 17

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Structural disease progression is a major concern for AS and PsA patients as it may prompt mobility loss - new data to provide further evidence on the efficacy of Cosentyx to reduce structural disease progression.

FDA Approves Simponi Aria for Psoriatic Arthritis and Ankylosing Spondylitis

Janssen Biotech, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).

Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis

Mease et al has reported in the NEJM the results of a phase 3 trial showing tofacitinib (Tofa) to be significantly more effective than placebo in active psoriatic arthritis (PsA) patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) therapies.